ProVerum and the EIC Accelerator: A Prostate Stent FDA Approved

An enlarged prostate, benign prostatic hyperplasia (BPH), squeezes the urethra and makes urination difficult for millions of older men. ProVerum, a spin-out from Trinity College Dublin, developed ProVee: a nitinol stent placed through a narrow video-guided scope that gently holds the prostatic urethra open, without cutting, burning or removing tissue, according to the company.

The European Innovation Council backed ProVerum twice: a €2.5 million grant under its pilot in 2020, and an equity-only award, listed as "ProVee II", at the June 2021 cut-off. Since then the company has raised €30 million and $80 million from private investors and, in December 2025, won FDA approval. By the measures that matter, it is a success. What the public record does not show is whether the EIC's 2021 equity was ever invested.

Where ProVerum Stands Today

On 9 December 2025 the FDA approved the ProVee System, according to the company and UroToday. The approval rested on ProVIDE, a randomised, double-blind, sham-controlled trial that the company says met all primary and secondary endpoints, with symptom relief and better urinary flow through 12 months and no device- or procedure-related serious adverse events.

Four months earlier, ProVerum had closed an $80 million Series B led by MVM Partners, with OrbiMed and the Ireland Strategic Investment Fund joining Gilde Healthcare, Lightstone Ventures, Atlantic Bridge and Enterprise Ireland. Trinity College Dublin called it the largest round ever raised by an Irish university spin-out. The company said the proceeds would be used "to prepare for commercialization".

The Technology: Holding the Urethra Open

ProVee takes a mechanical route rather than removing or destroying tissue: a stent-like expander, delivered through a scope the same diameter as the one urologists use to diagnose BPH, so it can be placed in an office setting. The company says it preserves sexual function and does not require a catheter after the procedure.

What the EIC Award Was, and What the Record Shows

The 2020 grant was for ProVee, "ProVee CE Mark and EU commercialisation plan", a grant-only award at the January 2020 cut-off of the EIC Accelerator pilot under Horizon 2020, according to the European Commission's winner list. It ran from May 2020 to April 2022 with an EU contribution of €2,499,999 towards a total cost of €3,750,635, and promised clinical evidence from a 50-patient CE trial and CE Mark approval, according to CORDIS. The final report records validated manufacturing processes, MDR compliance, a full FDA Investigational Device Exemption in December 2021 and the first patient enrolled in the US ProVIDE study in the second quarter of 2022. It does not report a CE trial or a CE mark, and we found no announcement of a CE mark since.

The June 2021 award to ProVerum was equity only: no grant, and therefore no CORDIS project or report. Silicon Republic reported it among five Irish EIC winners in October 2021. The funded technology, the ProVee System, has since been approved. But the EIC Fund is not named in the January 2022 Series A announcement or in the 2025 Series B, and we found no public record of an EIC Fund investment.

1. A pivotal US trialDeliveredProVIDE, sham-controlled, met all endpoints per the company.
2. FDA approvalDelivered9 December 2025.
3. Private follow-on capitalDelivered€30M Series A and $80M Series B.
4. EIC equity investedNot disclosedEIC Fund not named in any round.

What Has Happened Since the Award

The Money

ProVerum's early public funding came from EIT Health (€50,000 in 2016), the EIC pilot grant (€2.5 million in 2020) and Ireland's Disruptive Technologies Innovation Fund (€2.94 million in 2021), according to EIT Health. The private rounds that followed were far larger: the Series B alone, reported at €68.6 million by EU-Startups, was more than 25 times the EIC grant.

Why Europe Should Care

ProVerum is an Irish university spin-out that has taken a medical device all the way to FDA approval, with Irish state funds among its investors. Its first market is the US, where the company says more than 12 million men are actively managed for BPH. European patients would need a CE mark, which we found no announcement of.

The Verdict

ProVerum has not been asked for comment for this article. It is based entirely on public records, company statements and EU announcements, linked throughout.